Capricor Therapeutics Inc

+0.24 (+5.83%)
Earnings Announcements

Capricor Therapeutics Reports Q3 2020 Results

Published: 11/12/2020 21:12 GMT
Capricor Therapeutics Inc (CAPR) - Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Q3 Loss per Share $0.20.
As of September 30, 2020, Co's Cash, Cash Equivalents and Marketable Securities Totaled About $35.3 Million.
Revenue is expected to be $0.21 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.